沈晨光，博士毕业于厦门大学，师从夏宁邵院士；于中国科学院微生物研究所从事博士后研究工作，师从高福院士；先任职南方医科大学公共卫生学院教授，博导，博士后合作导师，生物安全三级实验室副主任，广东省杰出青年基金获得者，全球前2%顶尖科学家。国家自然科学基金评审专家，高等学校大学生医学创新竞赛委员会委员兼副秘书长，广东省热带医学学会常务理事兼副秘书长，广东省预防医学会慢性肺部疾病防控专委会副主委，广东省预防医学会疫苗循证专业委员会副主委，中国疫苗行业协会疫苗基础研究专委会委员，中国研究型医院学会细胞外囊泡研究与应用专委会委员委员，广东省健康科普促进会生物安全分会常委，广东省医学会感染病分会常委，广东省预防医学会病原微生物与生物安全专委会常委，Exploration学术编辑，hlife青年编委，《医学动物防制》编委，Nova Science Publishers出版社书籍主编 。主要从事人类重要传染病抗体与疫苗研究，主持6项国家自然科学基金，以第一或通讯作者（含并列）在JAMA、Scienc、Science Translational Medicine、Nature Communications等发表SCI论文40多篇，获授权专利20项。

人类病原抗体、疫苗、诊断试剂研发

1.        Shen C^#., Wang Z^#., Zhao F^#., Yang Y^#., Li J., Yuan J., Wang F., Li D., Yang M., Xing L., Wei J., Xiao H., Yang Y., Qu J., Qing L., Chen L., Xu Z., Peng L., Li Y., Zheng H., Chen F., Huang K., Jiang Y., Liu D., Zhang Z^*., Liu Y^*., Liu L^*. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA, 2020, 323(16):1582-1589. (Article,网站封面，2020年JAMA热点论文首位).

2.        Wu Y^#*., Wang F^#., Shen C^#., Peng W^#., Li D^#., Zhao C., Li Z., Li S., Bi Y., Yang Y., Gong Y., Xiao H., Fan Z., Tan S., Wu G., Tan W., Lu X., Fan C., Wang Q., Liu Y., Zhang C., Qi J., Gao GF*., Gao F*., Liu L*., A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. (2020). Science, 2020, 368(6496):1274-1278.

3.        Shen C^#., Chen J^#., Li R^#., Zhang M^#., Wang G^#., Stegalkina S., Zhang L., Chen J., Cao J., Bi X., Anderson SF., Alefantis T., Zhang M., Cai X., Yang K., Zheng Q., Fang M., Yu H., Luo W., Zheng Z., Yuan Q., Zhang J., Wai-Kuo Shih J., Kleanthous H., Chen H., Chen Y*., Xia N*. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Science translational medicine, 2017, 9(412), eaam5752.

4.        Shen C^#., Zhang M^#., Chen Y^#., Zhang L., Wang G., Chen J., Chen S., Li Z., Wei F., Chen J., Yang K., Guo S., Wang Y., Zheng Q., Yu H., Luo W., Zhang J., Chen H., Chen Y*., Xia N. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency [J]. Theranostics, 2019, 9(1): 210.

5.        Yang Y^#., Shen C^#., Li J^#., Yuan J., Wei J., Huang F., Wang F., Li G., Li Y., Xing L., Peng L., Yang M., Cao M., Zheng H., Wu W., Zou R., Li D., Xu Z., Wang H., Zhang M., Zhang Z., Gao GF., Jiang C*., Liu L*., Liu Y*. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. JACI. 2020, 146(1): 119-127.

6.        Zhang Y^#., Wang S^#., Wu Y^#., Hou W^#., Yuan L^#., Shen C^#., Wang J., Ye J., Zheng Q., Ma J., Xu J., Wei M., Li Z., Nian S., Xiong H., Zhang L., Shi Y., Fu B., Cao J., Yang C., Li Z., Yang T., Liu L., Yu H., Hu J., Ge S., Chen Y., Zhang T., Zhang J., Cheng T*., Yuan Q*., Xia N*. Virus‐free and live‐cell visualizing SARS‐CoV‐2 cell entry for studies of neutralizing antibodies and compound inhibitors[J]. Small Methods, 2020: 2001031.

7.        Liu C^#., Mendonça L^#., Yang Y^#., Gao Y^#., Shen C^#., Liu J., Ni T., Ju B., Liu C., Tang X., Wei J., Ma X., Zhu Y., Liu W., Xu S., Liu Y., Yuan J., Wu J., Liu Z.,Zhang Z*., Liu L*., Wang P*., Zhang P*. The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET. Structure. 2020, 28(11): 1218-1224.

8.        Yang Y^#., Shen C^#., Li J., Zou R., Wong G., Peng L., Yang L., Fang S., Li J., Li X., Wu W., Jiang X., Zeng L., Lan J., Bi Y., Gao GF., Yuan J*., Liu Y*. Clinical and virological characteristics of human infections with H7N9 avian influenza virus in Shenzhen, China, 2013-2017. J Infect. 2019, 79(4):389-399.

9.        Xiong HL^#., Cao JL^#., Shen CG^#., Ma J., Qiao XY., Shi TS., Ge SX., Ye HM., Zhang J., Yuan Q*., Zhang TY*., Xia NS*. Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro. Frontiers in Pharmacology. 2019, 79(4):389-399.

10.    Li Y^#., Shen C^#., Yang L^#., Yang Y., Wang M., Li S., Chen F., Yang M., Peng L., Ma J., Duan Z*., Li L*., Liu Y*. Intra-host diversity of hepatitis B virus during mother-to-child transmission: the X gene may play a key role in virus survival in children after transmission. Arch Virol. 2020.

11. Li, Xiaohe^#; Shen,Chenguang^#*; Wang, Lifei^#; Majumder, Sumit; Zhang, Die; Deen, M. Jamal; Li, Yanjie; Qing, Ling; Zhang, Ying; Chen, Chuming; Zou, Rongrong; Lan, Jianfeng; Huang, Ling; Peng, Cheng; Zeng, Lijiao; Liang, Yanhua; Cao, Mengli; Yang, Yang; Yang, Minghui; Tan, Guoyu; Tang, Shenghong; Liu, Lei*; Yuan, Jing; Liu*, Yingxia*; Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: a cohort study, Respiratory Research, 2021, 22(1): 0-203.

12.  Shen,Chenguang^#*; Xu, Yi^#; Ji, Jingkai^#; Wei, Jinli^#; Jiang, Yujin^#; Yang, Yang; Yang, Minghui; Huang, Huaxin; Zou, Rongrong; Fang, Chunxiao; Zeng, Fansen; Yang, Fengxia; Wang, Xinfa; Yuan, Jing; Li, Jianmin; Wang, Xianfeng; Yang, Huanming; Gong, Sitang; Wang, Hui; Xia, Huimin*; Ma, Jinmin*; Liu, Yingxia*; Intestinal microbiota has important effect on severity of hand foot and mouth disease in children, BMC Infectious Diseases, 2021, 21(1): 0-1062